Price
$0.49
Decreased by -0.08%
Dollar Volume (20D)
38.28 K
ADR%
5.97
Earnings Report Date (estimate)
Jun 19, 23 (-0.1)
Market Cap.
21.86 M
Shares Float
35.55 M
Shares Outstanding
44.61 M
Beta
1.52
Price / Earnings
-1.48
BPR
132.50
20D Range
0.46 0.57
50D Range
0.41 0.57
200D Range
0.34 0.93
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Jun 21, 22 -0.04
Increased by +92.73%
-0.13
Increased by +532.54%
Feb 14, 22 -0.11
Decreased by -105.67%
-0.08
Decreased by -468.75%
Feb 9, 21 -0.16
Increased by +85.71%
-0.41
Increased by +148.72%
Nov 16, 20 -0.10
Increased by +96.32%
-0.56
Increased by +146.68%
Aug 13, 20 -0.55
Increased by +54.17%
-0.61
Increased by +16.12%
Jun 29, 20 1.94
Increased by +210.23%
-0.92
Increased by +337.90%
Feb 14, 20 -1.12
Decreased by -100.00%
-1.03
Decreased by -8.48%
Nov 13, 19 -2.72
Increased by +45.16%
-0.92
Decreased by -212.67%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 22 0.00
Decreased by N/A%
-3.89 M
Decreased by -27.84%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-4.93 M
Decreased by -188.92%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 32.00 K
Increased by +N/A%
-4.52 M
Decreased by -53.25%
Decreased by -14.14 K%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-4.02 M
Increased by +57.26%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-3.04 M
Increased by +31.46%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
5.54 M
Increased by +158.05%
Increased by +N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-2.95 M
Increased by +43.35%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 115.00 K
Increased by +N/A%
-9.40 M
Decreased by -124.65%
Decreased by -8.18 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.